Skip to main content

Table 1 Sample characteristics

From: How healthy participants value additional diagnostic testing with amyloid-PET in patients diagnosed with mild cognitive impairment — a bidding game experiment

 

Not interested in testing

Interested in testing

 

All

Condition A

Condition B

Condition C

N = 193 (13%)

N = 1238 (87%)

N = 408

N = 413

N = 417

Age

66 ± 7

65 ± 8

65 ± 8

64 ± 8

66 ± 8

Female sex, n (%)

160 (83%)

929 (75%)

307 (75%)

314 (76%)

308 (74%)

Education, Verhage  [22]

6 ± 1

6 ± 1

6 ± 1

6 ± 1

6 ± 1

Positive family history

140 (73%)

905 (73%)

312 (76%)

296 (72%)

297 (71%)

Cared for person with dementia, n (%)

72 (51%)

444 (49%)

156 (50%)

136 (46%)

152 (51%)

Income, n (%)

  < €1000

3 (2%)

18 (2%)

5 (1%)

3 (1%)

10 (2%)

 €1000–€2500

70 (36%)

367 (30%)

121 (30%)

117 (28%)

129 (31%)

 €2500–€5000

83 (43%)

537 (44%)

171 (42%)

182 (44%)

184 (44%)

  > €5000

14 (7%)

141 (11%)

44 (11%)

56 (14%)

41 (10%)

 Unknown

22 (11%)

172 (14%)

66 (16%)

53 (13%)

53 (13%)

Attended memory clinic, n (%)

 Yes, for myself

6 (3%)

46 (4%)

18 (4%)

14 (3%)

14 (3%)

 Yes, for my spouse

28 (15%)

190 (15%)

69 (17%)

65 (16%)

56 (13%)

 Yes, for myself and my spouse

2 (1%)

21 (2%)

6 (1%)

7 (2%)

8 (2%)

 Not sure

8 (4%)

47 (4%)

16 (4%)

15 (4%)

16 (4%)

 No

149 (77%)

934 (75%)

299 (73%)

312 (76%)

323 (77%)

Worries for AD

103 (54%)

797 (64%)

264 (65%)

271 (66%)

263 (63%)

EQ-5D-5L utility score

0.87 ± 0.13

0.86 ± 0.15

0.86 ± 0.15

0.87 ± 0.15

0.85 ± 0.17

EQ-5D VAS

84 ± 19

84 ± 17

84 ± 18

84 ± 17

83 ± 17

STAI

13 ± 2

13 ± 2

13 ± 3

13 ± 2

13 ± 2

Device used to complete questionnaire

 Desktop

111 (58%)

741 (60%)

240 (59%)

242 (59%)

259 (62%)

 Tablet

24 (12%)

96 (8%)

33 (8%)

34 (8%)

29 (7%)

 Smartphone

193 (30%)

401 (32%)

135 (33%)

137 (33%)

129 (31%)

  1. AD Alzheimer’s disease, EQ-5D-5L 5-level version of EuroQol-5 Dimension, VAS visual analog scale, STAI State-Trait Anxiety Inventory. Condition A, the result of the amyloid-PET scan results in better patient management (not further specified); condition B, same as condition A and a delay in institutionalization of 3 months; condition C, same as A and a delay in institutionalization of 6 months